Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ossein hydrolysate is a complex mixture of peptides derived from the hydrolysis of ossein, which is the organic, collagen-rich matrix of animal bones. [2, 5, 12] Rich in Type I collagen peptides, this substance provides the amino acid building blocks necessary for bone and connective tissue. [6] It is considered highly bioavailable and is investigated for its osteogenic (bone-forming) properties. [1, 5] Research suggests that these peptides can promote bone health by stimulating the proliferation and differentiation of osteoblasts (bone-forming cells) and upregulating the expression of key bone matrix proteins like osteocalcin and collagen. [1, 17] Ossein hydrolysate is a primary component of the ossein-hydroxyapatite complex (OHC), a pharmaceutical product and dietary supplement used to prevent bone loss, treat osteoporosis, and accelerate fracture healing. [6, 8, 9, 10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ossein hydrolysate.